Kunena :: Тема: Posted by dogtcisexan1984 on 29.11.2016 17:36:12: br 21 erlotinib (1/2)

Навигация: Главная Форум Главный раздел Сообщество базовых площадокPosted by dogtcisexan1984 on 29.11.2016 17:36:12: br 21 erlotinib

Добро пожаловать, Гость

Форум

Главный раздел

Сообщество базовых площадок

Posted by dogtcisexan1984 on 29.11.2016 17:36:12: br 21 erlotinib

Страница:
1
2

ТЕМА: Posted by dogtcisexan1984 on 29.11.2016 17:36:12: br 21 erlotinib

Posted by dogtcisexan1984 on 29.11.2016 17:36:12: br 21 erlotinib 7 года 5 мес. назад #922

akipk

High Quality - Low Cost Anti-Cancer Drugs

*
Tarceva (erlotinib): "In March 11, 2011 I was diagnosed with stage 4 lung cancer. My oncologist prescribed Tarceva one a day 150 mg. I had the normal side effects; diarrhea and rash. Both were controlled, the rash was treated with antibiotics and the diarrhea just went away by itself. I understand this pill is a maintenance therapy pill. It seems to work well on me. Tomorrow, April 18 is my appointment, had an X-ray yesterday. I still have to know the outcome, but I am already feeling well. I had toracentesis before my diagnosis due to pleural effusion. Reading the posts here in this site gives me positive hope that Tarceva works well for patient's with NSCLC."
are gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774).
The subject has received prior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment; prior erlotinib is required and does not require a 14-day wash out
gofishtalk.com/profiles/blogs/posted-by-...5-24-29-tarceva-dose
Corneal ulcerations or perforations have been reported in patients receiving Tarceva treatment. Abnormal eyelash growth including in-growing eyelashes, excessive growth and thickening of the eyelashes have been reported and are risk factors for corneal ulceration/perforation.
The person's disease responds to the first 2 cycles of treatment with erlotinib and
Erlotinib hydrochloride hydrate is formed from an aqueous solution and is useful as a pharmaceutical and as a purification intermediate.
bus-rostov.ru/forum/razdel-predlozhenij/...for-lung-cancer.html
Re: TARCEVA y referencias
For those suffering from a rash caused by Tarceva, the dry, pimple-like boils on the skin and scalp can be itchy and painful. Some people may develop severe rashes that require more aggressive medical intervention. Keep your oncology nurse and doctor updated about your rash and notify them immediately of any new symptoms or if the rash is getting worse.
The presence of certain mutations in EGFR can predict the response to EGFR TKIs [16 ]. In published reports, response rates to EGFR TKIs are generally higher than platinum-based chemotherapy in patients with NSCLC whose tumors harbor EFGR-activating mutations [7. 17 ]. The EURTAC trial tested this hypothesis in patients whose NSCLC contained EGFR exon 19 deletions or exon 21 (L858R) substitution mutations. In EURTAC, the 5.2-month increase in median PFS for erlotinib compared with platinum-doublet chemotherapy was both clinically important and statistically robust. The treatment effect was further supported by the approximately fourfold increase in ORR for patients on the erlotinib arm compared with the standard platinum-based doublet chemotherapy arm. Although the EURTAC trial did not demonstrate a statistically significant improvement in OS in the erlotinib arm as compared with chemotherapy, this may have been confounded by postprogression treatment with an EGFR-directed TKI, which in all but two cases involved subsequent erlotinib. The analysis of adverse drug reactions in the EURTAC trial did not identify new, clinically significant safety signals, and in the context of the efficacy results, the benefits of erlotinib outweighed its risks.
To evaluate the efficacy and safety by treating the advanced non small cell lung cancer (NSCLC) patients who have failure of standard dose EGFR-TKIs(Erlotinib or Gefitinib ) with high-dose, pulsatile Erlotinib(450mg every 3 days) or Gefitinib (1000mg every 4 days)
Experimental: gemcitabine + erlotinib
We conducted a randomized, placebo-controlled, double-blind trial to determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non?small.
Common Questions and Answers about Tarceva j code
des2pro.ru/forum/dobro-pozhalovat/4495-p...-48-tarceva-gi-bleed
"We are pleased that the EURTAC study so quickly revealed Tarceva may be a viable alternative to platinum-based chemotherapy in newly diagnosed NSCLC patients with EGFR activating mutations," said Naoki Okamura, chief executive officer, OSI Pharmaceuticals. "The interim analysis of the EURTAC study reinforces the role that Tarceva may have in treating patients beyond the Asian population, which has a historically higher instance of EGFR activating mutations."
The letter also warned that patients treated with Tarceva experienced corneal perforation or ulceration; disorders including abnormal eyelash growth, keratoconjunctivitis sicca, and keratitis, have also been observed.
This study examined the efficacy and safety of erlotinib combined with cisplatin and gemcitabine for first-line treatment of advanced NSCLC. Overall, the erlotinib combination did not show any survival benefit compared with chemotherapy alone; median OS was 43 weeks for erlotinib plus chemotherapy and 44.1 weeks for placebo plus chemotherapy. There were no significant differences in TTP, RR, or time to symptomatic progression (QoL) between the two groups. Similar results were reported from a phase III trial of erlotinib plus carboplatin and paclitaxel (TRIBUTE [Tarceva responses in conjunction with paclitaxel and carboplatin]), in advanced NSCLC. 37 These results are also consistent with phase III trials of the EGFR TKI gefitinib combined with platinum-based chemotherapy. 38 ,39
Age of people who have Joint Aches when taking Tarceva *:
Things to avoid while having tarceva
I think Tarceva is more convenient than chemo since with chemo we have no control over the dosage – the doctors do - whereas with Tarceva we can adjust the dosage, skip a dose if the side effects get too unbearable, etc.
Tarceva, Marketed Details the Europe (EU)
cubcoins.ru/index.php/forum
Sono stati identificati 11 studi, pubblicati tra la fine del 2004 e il 2008 per un totale di 106 pazienti con carcinoma del polmone non a piccole cellule, con malattia progressiva nonostante Gefitinib 250 mg/die. Questi pazienti ( per il 72,6% donne, per l’85,1% con adenocarcinoma, e per il 75,3% mai fumatori ) sono stati trattati con Erlotinib 150 mg, 1 volta die.
Thursday 20th February 2014 start TARCEVA 150mg tablets (Erlotinib)
dear all, my dad is a lung cancer patient, and his doctor plan to him is too start taking TARCEVA, do you thik that was a good choice. regards, lena
Tarceva Dosing for Pancreatic Cancer
Tarceva Prescription Discounts
Ik ben zeer tevreden over de resultaten van tarceva.Na twee zware chemokuren kon ik niet bestraalt worden omdat ik van twee tumoren. na de chemo er vier bij had gekregen.Nu ruim 11 maanden tarceva gebruik ,is er nog maar 1 tumor duidelijk te zien.En die is geslonken van 2,6mm naar 0,9 mm.Dus ik ben er erg blij mee.De bijwerkingen van huiidproblemen,dunner wordend haar [lees meer. ] en enorme darmklachten neem ik dan er maar bij.IK eet nog steeds heel goed,drink erg veell ,zeker 16 bekers vocht dit om het vochtverlies door de darm klachten op peil te houden.Ik begon met 150mg en na 3 maanden overgestapt op 100mg en dat bevalt erg goed.\de bijwerkingen zijn wat minder heftig en daardoor beter te verdragen. Ik ben zeer tevreden over de resultaten van tarceva.Na twee zware chemokuren kon ik niet bestraalt worden omdat ik van twee tumoren. na de chemo er vier bij had gekregen.Nu ruim 11 maanden tarceva gebruik ,is er nog maar 1 tumor duidelijk te zien.En die is geslonken van 2,6mm naar 0,9 mm.Dus ik ben er erg blij mee.De bijwerkingen van huiidproblemen,dunner wordend haar en enorme darmklachten neem ik dan er maar bij.IK eet nog steeds heel goed,drink erg veell ,zeker 16 bekers vocht dit om het vochtverlies door de darm klachten op peil te houden.Ik begon met 150mg en na 3 maanden overgestapt op 100mg en dat bevalt erg goed.\de bijwerkingen zijn wat minder heftig en daardoor beter te verdragen.
dnz2.rosvita.rv.ua/index.php/forum/skrin...ib-plus-chemotherapy
Craig Yes I see your point about preparing for the worst. It makes sense. Like a disaster kit. Did you ever take Tarceva? do you have the mutation? Hope you continue to do well on new drug trials.
Tarceva's main rival will be Aventis' Taxotere, a $1-billion-plus product and the only drug approved as a second treatment for lung cancer. By the time Tarceva reaches the market, however, it will probably also face Eli Lilly & Co.'s Alimta, another chemotherapy drug.
Alopecia is found among people who take Tarceva, especially for people who are female, 60+ old. have been taking the drug for 1 - 6 months, also take medication Avastin, and have Lung neoplasm malignant. We study 19,048 people who have side effects while taking Tarceva from FDA and social media. Among them, 194 have Alopecia. Find out below who they are, when they have Alopecia and more.
aum.com.ru/forum/10--/6103-posted-by-tin...va-global-sales#6103
In vitro assays of cytochrome P450 metabolism showed that erlotinib is metabolized primarily by CYP3A4 and to a lesser extent by CYP1A2, and the extrahepatic isoform CYP1A1.
amorc-spb.ru/forum/dobro-pozhalovat/1883...52-tarceva-pill-size
For the complete drug label text with sections containing pharmacogenetic information highlighted, see the Erlotinib EMA drug label .
For the upset stomach, her onc told her it would be OK to take a 10mg Pepcid AC 12 hours opposite of when she takes Tarceva. (Yeah, we know that Tarceva requires an acidic gut environment for absorption, but apparently after 12 hours it’s OK to neutralize some of the acid.)
C]-erlotinib as a radiotracer,
[Show abstract] [hide] ABSTRACT: Although treatment with cytotoxic agents has produced modest survival improvement in patients with stage III and IV non-small cell lung cancer (NSCLC), it appears that a plateau has been reached with currently available chemotherapeutic regimens. Increasing knowledge regarding the properties of malignant neoplasms has identified a number of potential therapeutic targets. The epidermal growth factor receptor (EGFR) is one of these targets. Preclinical models have revealed that tumour growth can be inhibited by monoclonal antibodies directed against EGFR and EGFR-specific tyrosine kinase inhibitors. Erlotinib (Tarceva trade mark; OSI Pharmaceuticals, Genentech and Roche), a quinazoline derivative with good oral absorption, is one of several EGFR tyrosine kinases that has been studied in clinical trials. In a Phase I study, mild diarrhoea and mild rash were the most common toxicities. At a dose of 200 mg/day, diarrhoea was the dose-limiting toxicity. The observation that EGFR overexpression is relatively common in NSCLC led to a Phase II trial of erlotinib at the maximum-tolerated dose (150 mg/day) in previously treated NSCLC patients. Erlotinib produced a 12% response rate and there was no apparent relationship between response and tumour EGFR levels. More recent reports suggest that patients who develop a rash have higher responses. Based on its single agent activity, erlotinib has been evaluated in two Phase III trials which compared erlotinib plus chemotherapy to chemotherapy alone in previously untreated NSCLC patients. Erlotinib has also been compared to placebo in a Phase III trial which was limited to advanced stage NSCLC patients whose disease had progressed after two previous chemotherapy regimens. The optimum use of erlotinib in NSCLC will be determined by the results of the completed and future Phase III trials.